Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib in advanced NSCLC with EGFR mutation
NCT03452150Phase 1Completed
- Sponsor
- InventisBio
- Start
- Jan 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by InventisBio. Primary endpoints: Dose Limiting Toxicities, Adverse events and 3 more. Started Jan 2018; status: completed.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03452150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452150.